GlassScriptPhysician profile
Jehuda Renan
NPI 1578741823
$960.15
in general payments reported to CMS, 2019-2025
15 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.25 · 2020: $61.72 · 2021: $259 · 2022: $173 · 2023: $96.08 · 2024: $157 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.08 | 2020-2023 | |
| Hologic Sales and Service, LLC | $76.16 | 2023-2024 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Exact Sciences Corporation | $58.23 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $57.82 | 2023-2024 | |
| Coopersurgical, INC. | $55.27 | 2020-2025 | Paragard T 380a |
| Mayne Pharma Commercial LLC | $53.63 | 2024-2025 | |
| Becton, Dickinson and Company | $32.74 | 2019 | |
| Dexcom, INC. | $29.58 | 2025 | Dexcom G6 Transmitter |
| Myovant Sciences INC. | $27.79 | 2021 | |
| Mimedx Group, INC. | $27.35 | 2025 | |
| Sumitomo Pharma America, INC. | $26.25 | 2025 | Myfembree |
| Boston Scientific Corporation | $23.74 | 2019 | |
| Channel Medsystems, INC. | $20.57 | 2022 | |
| Exeltis, USA INC. | $17.17 | 2023 | Slynd |
| Allergan, INC. | $14.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jehuda Renan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.